Joseph Loscalzo

CIK: 0001276128

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (25.9%)

Position reduction

Option Exercises (M)13 (48.1%)

Derivative conversions

Awards (A)7 (25.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

IONS

IONIS PHARMACEUTICALS INC

Director

CYPH

CYPHERPUNK TECHNOLOGIES INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (27 total)

IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2026
Award(A)
Restricted Stock Unit
Direct
2.3K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
5.4K shares-
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Sale(S)
Direct
59.5K shares at avg. $74.90$4.5M
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Sale(S)
Direct
17.8K shares at avg. $75.58$1.3M
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Exercise(M)
Direct
11K shares at avg. $38.06$417K
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Exercise(M)
Direct
12K shares at avg. $40.05$481K
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Exercise(M)
Direct
10.3K shares at avg. $41.08$424K
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Exercise(M)
Direct
16K shares at avg. $42.88$686K
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Exercise(M)
Direct
12K shares at avg. $60.20$722K
IONS
IONIS PHARMACEUTICALS INC
May 4, 2026
Exercise(M)
Direct
16K shares at avg. $64.80$1.0M
CYPH
CYPHERPUNK TECHNOLOGIES INC.
Mar 13, 2026
Exercise(M)
Direct
94.1K shares-
CYPH
CYPHERPUNK TECHNOLOGIES INC.
Mar 13, 2026
Exercise(M)
Direct
74.7K shares-
IONS
IONIS PHARMACEUTICALS INC
Mar 4, 2026
Exercise(M)
Direct
200 shares at avg. $38.06$8K
IONS
IONIS PHARMACEUTICALS INC
Mar 4, 2026
Sale(S)
Direct
200 shares at avg. $80.00$16K
IONS
IONIS PHARMACEUTICALS INC
Mar 3, 2026
Sale(S)
Direct
832 shares at avg. $80.33$67K
IONS
IONIS PHARMACEUTICALS INC
Mar 3, 2026
Exercise(M)
Direct
832 shares at avg. $38.06$32K
CYPH
CYPHERPUNK TECHNOLOGIES INC.
Dec 23, 2025
Award(A)
Restricted Stock Units
Direct
94.1K shares-
CYPH
CYPHERPUNK TECHNOLOGIES INC.
Nov 11, 2025
Award(A)
Restricted Stock Units
Direct
74.7K shares-
IONS
IONIS PHARMACEUTICALS INC
Oct 31, 2025
Sale(S)
Direct
16K shares at avg. $75.10$1.2M
IONS
IONIS PHARMACEUTICALS INC
Oct 31, 2025
Exercise(M)
Direct
16K shares at avg. $52.22$836K
IONS
IONIS PHARMACEUTICALS INC
Sep 3, 2025
Sale(S)
Direct
16K shares at avg. $60.15$962K
IONS
IONIS PHARMACEUTICALS INC
Sep 3, 2025
Exercise(M)
Direct
16K shares at avg. $24.42$391K
IONS
IONIS PHARMACEUTICALS INC
Jul 15, 2025
Exercise(M)
Direct
4.1K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
11.5K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2025
Award(A)
Restricted Stock Unit
Direct
5.2K shares-

		Type	Shares	Price		Ownership
Jul 1, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Restricted Stock Unit	2,301	-	-	Direct
Jul 1, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Non-Qualified Stock Option (right to buy)	5,369	-	-	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	59,508	$74.90	$4,457,292	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	17,781	$75.58	$1,343,934	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	10,968	$38.06	$417,442	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	12,000	$40.05	$480,600	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	10,321	$41.08	$423,987	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	16,000	$42.88	$686,080	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	12,000	$60.20	$722,400	Direct
May 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	16,000	$64.80	$1,036,800	Direct
Mar 13, 2026	CYPH CYPHERPUNK TECHNOLOGIES INC.	Exercise(M)	94,050	-	$0	Direct
Mar 13, 2026	CYPH CYPHERPUNK TECHNOLOGIES INC.	Exercise(M)	74,700	-	$0	Direct
Mar 4, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	200	$38.06	$7,612	Direct
Mar 4, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	200	$80.00	$16,000	Direct
Mar 3, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	832	$80.33	$66,833	Direct
Mar 3, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	832	$38.06	$31,666	Direct
Dec 23, 2025	CYPH CYPHERPUNK TECHNOLOGIES INC.	Award(A) Restricted Stock Units	94,050	-	-	Direct
Nov 11, 2025	CYPH CYPHERPUNK TECHNOLOGIES INC.	Award(A) Restricted Stock Units	74,700	-	-	Direct
Oct 31, 2025	IONS IONIS PHARMACEUTICALS INC	Sale(S)	16,000	$75.10	$1,201,669	Direct
Oct 31, 2025	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	16,000	$52.22	$835,520	Direct
Sep 3, 2025	IONS IONIS PHARMACEUTICALS INC	Sale(S)	16,000	$60.15	$962,371	Direct
Sep 3, 2025	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	16,000	$24.42	$390,720	Direct
Jul 15, 2025	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	4,079	-	-	Direct
Jul 1, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A) Non-Qualified Stock Option (right to buy)	11,518	-	-	Direct
Jul 1, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A) Restricted Stock Unit	5,220	-	-	Direct

1-25 of 27 transactions

About LOSCALZO JOSEPH

LOSCALZO JOSEPH (SEC CIK 0001276128) files insider reports with the SEC as Director of IONIS PHARMACEUTICALS INC (IONS) and Director of CYPHERPUNK TECHNOLOGIES INC. (CYPH).

Signal8 holds 12 ownership filings by LOSCALZO JOSEPH, all Form 4s, filed between Oct 4, 2024 and Jul 6, 2026. Those filings report 27 transactions, from Oct 2, 2024 to Jul 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LOSCALZO JOSEPH's filings is in CARLSBAD, CA.

Recent filings by LOSCALZO JOSEPH

Jul 1, 2026: Grants or awards of IONS derivative securities (2 lines, Form 4, code A).
May 4, 2026: Open-market sales of IONS shares (2 lines, Form 4, code S).
May 4, 2026: Option exercises of IONS shares (6 lines, Form 4, code M).
Mar 13, 2026: Option exercises of CYPH shares (2 lines, Form 4, code M).
Mar 4, 2026: Option exercise of IONS shares (Form 4, code M).

Other insiders filing for IONIS PHARMACEUTICALS INC (IONS)

Devers Shannon L., EVP, Chief Human Resources Ofc
Swayze Eric, EVP Research
BENNETT C FRANK, EVP, Chief Scientific Officer
O'NEIL PATRICK R., EVP CLO & General Counsel
Monia Brett P, Chief Executive Officer
Birchler Brian, EVP, Corp and Development Ops

How to read Form 4 transaction codes